News

Filter
Filter

02 / 26 / 2025

Perthera Report® Pancreatic Version Now Available, Revolutionizing Chemo Selection for Pancreatic Cancer Treatment

First-of-Its-Kind AI Predictor Eliminates Guesswork in Frontline Chemotherapy Selection, Empowering Oncologists with Unprecedented Data-Driven Insights MCCLEAN, VA, UNITED STATES, February 26, 2025 — Perthera, The Therapeutic Intelligence Company, today announced the launch of the Perthera Report® Pancreatic version (PRPv)—a game-changing precision oncology tool designed to revolutionize pancreatic cancer treatment for newly diagnosed patients with metastatic cancer being treated at frontline. This new version of the Perthera Report was designed specifically for oncologists treating pancreatic cancer patients and includes Perthera’s recently announced frontline chemotherapy predictor. Perthera’s ranked therapy report uniquely uses a patient’s prior medical history and molecular test results to precisely rank […]

Read More
EIN Presswire PDF

01 / 23 / 2025

Perthera to Present Research Validating World’s First AI-Driven Chemo Predictor at 2025 ASCO GI Cancers Symposium

MCCLEAN, VA, UNITED STATES, January 23, 2025 — Perthera, a leader in precision oncology, will present follow-on research and validation of the world’s first AI-driven chemo predictor for frontline treatment in pancreatic cancer (PDAC) at the 2025 ASCO Gastrointestinal Cancers Symposium. This groundbreaking advancement, PDACai, was first discussed at ASCO 2023 and has since undergone significant advancements and extensive validation efforts. The announcement of this breakthrough in the frontline treatment of pancreatic cancer was made on January 14, 2025. Perthera will be making this predictor available to ordering physicians and their patients as part of the Perthera Report Pancreatic Version (PV) in […]

Read More
EIN Presswire PDF

01 / 14 / 2025

Perthera Announces Breakthrough in Pancreatic Cancer, World’s First AI-Driven Chemo Predictor for Frontline Treatment

MCCLEAN, VA, UNITED STATES, January 14, 2025 — Perthera, a leader in AI-driven precision oncology, announces a groundbreaking advancement in the fight against pancreatic adenocarcinoma (PDAC) with the introduction of PDACai, the world’s first validated artificial intelligence signature designed to predict front-line chemotherapy effectiveness for newly diagnosed patients. It will be available for ordering physicians in February 2025. Prior to PDACai, there has been no way for a treating clinician to know which of the two current most frequently used frontline treatments a patient would most likely respond to without trialing the patient on each of these drug regimens, losing […]

Read More
AIDecision SupportMolecular ProfilingTherapies
EIN Pressewire PDF

12 / 19 / 2024

Latest Perthera Report Further Advances AI-Powered Support for Personalized Cancer Therapies

MCCLEAN, VA, UNITED STATES, December 19, 2024 — Perthera, a leader in AI-driven precision oncology, announces the release of version 4.0 of The Perthera Report®, an innovative decision-support tool that helps oncologists synthesize vast amounts of data to identify the optimal therapy for patients. By transforming complex molecular and multi-omic data into ranked, actionable therapy options, The Perthera Report saves time, reduces complexity, and improves patient outcomes. Addressing the Growing Complexity of Cancer Care The Perthera Report 4.0 tackles the challenges oncologists face today, including the rapid expansion of biomarkers, therapies, and clinical trials, which has made interpreting molecular diagnostic […]

Read More
EINPresswire PDF

12 / 17 / 2024

Perthera Finds Survival Differences in Lung vs. Liver Metastasis in New Study

MCCLEAN, VA, UNITED STATES, December 16, 2024 /– Perthera, the leader in AI-driven Precision Oncology Decision Support, has unveiled groundbreaking research on Pancreatic Ductal Adenocarcinoma (PDAC) that links survival outcomes to the location of cancer metastasis. This study contributes to the large body of research conducted using Perthera’s proprietary data which includes patient medical history, multi-omic test findings, and real-world outcomes. Perthera has one of the largest databases in pancreatic cancer allowing for rich collaborations with researchers focused on this space. The study, encompassing data from 852 patients, highlights significantly longer survival for pancreatic cancer patients with lung metastases compared to those […]

Read More
Clinical ResearchDecision SupportPrecision Oncology
EINPresswire PDF

11 / 25 / 2024

Perthera Announces Landmark Study Showing Multi-omic Testing’s Role In Improving Outcomes For Metastatic Breast Cancer

MCLEAN, VA, UNITED STATES, November 25, 2024 — Perthera, the industry leader in Precision Oncology Decision Support, in collaboration with researchers from George Mason University and The Side-Out Foundation, announces the publication of a groundbreaking study emphasizing the transformative impact of multi-omic molecular testing in guiding treatment for metastatic breast cancer. This pivotal research utilized Perthera’s proprietary data from metastatic breast cancer patients, where genomic data was combined with proteomic testing to study the PI3K/AKT/mTOR pathway, a frequently disrupted signaling pathway in breast cancer. The study highlights how integrating genomic and proteomic data helps identify patients who would benefit most […]

Read More
Clinical ResearchMolecular ProfilingMultiomicsPrecision Oncology
EIN Presswire PDF

11 / 08 / 2024

Perthera, the Leading Therapeutic Intelligence Company, Releases vMTB 4.0, Accelerating AI Learning

MCLEAN, VA, UNITED STATES, November 7, 2024 — Perthera, the industry leader in Precision Oncology Decision Support, announces the release of the latest version of its patented Virtual Molecular Tumor Board application, vMTB 4.0. The vMTB 4.0 is used by Perthera’s tumor board members to finalize the ranked therapy options presented in the full-length Perthera Report. This “human in the loop” interaction provides feedback and adjustments to Perthera’s Therapeutic Intelligence Engine, accelerating it’s learning and continuously honing the precision of its therapeutic rankings. Using the vMTB application, selected specialists can review the case, comment, and interact asynchronously. Perthera’s vMTB application […]

Read More
Decision SupportThe Leadership Team
EIN Presswire PDF

07 / 10 / 2024

Perthera Names Marketing Veteran, Jeanne M. Cummins, Chief Marketing Officer (CMO)

Appointment Drives Growth and Market Expansion with Strategic Leadership for Perthera, a Pioneer in Precision Oncology Decision Support MCLEAN, VA // Perthera, The Therapeutic Intelligence Company® and the industry leader in Precision Oncology Decision Support, announces the appointment of industry veteran Jeanne M. Cummins as Chief Marketing Officer (CMO). Ms. Cummins will lead the company’s marketing initiatives to support its ambitious growth plans. This appointment marks a significant step in Perthera’s commercial development, following the assignment of a Category III CPT code for reimbursement in 2023. This recognition by the AMA was a pivotal moment, paving the way to make […]

Read More
Decision SupportThe Leadership Team
EIN Presswire PDF

05 / 31 / 2024

At ASCO ’24, Perthera Launches New Services Aimed at Easing Burden on Clinicians Delivering Precision Oncology Care

Chicago, IL – May 31, 2024 – Perthera has announced the addition of new services and capabilities to its Precision Oncology Platform suite aimed at making it easier for Oncologists to identify and deliver the best precision treatment for their patients.  The Perthera Precision Oncology Platform provides patented, AI-driven, ranked-therapy option decision support to oncologists, advocacy groups, and their staff. The addition of new capabilities makes it simpler to order a report and now come with an option to have Perthera handle the complex task of getting a patient on clinical trial or off-label therapy, if chosen by the treating […]

Read More
Decision SupportPrecision Oncology
EIN Presswire PDF

04 / 24 / 2024

Renowned Oncologist and Cancer Researcher, Dr. Derek Raghavan, Joins Perthera as Chief Medical Officer

Mclean, VA // Perthera, the industry leader in Precision Oncology Decision Support announces that Dr. Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, founding President of the Levine Cancer Institute and former Chair and Director of the Cleveland Clinic Taussig Cancer Institute, has joined Perthera as Chief Medical Officer (CMO). Dr. Raghavan’s appointment underscores Perthera’s commitment to advancing precision oncology and transforming decision making for oncologists, especially those practicing in a community setting, who are confronted by the ever-increasing complexity in making treatment decisions. “I look forward to helping Perthera reach the full potential of their best-in-class AI-based treatment decision support […]

Read More
Precision OncologyThe Leadership Team
EIN Presswire PDF

THIS IS AI-POWERED PRECISION ONCOLOGY

Contact Us